While humans can regularly replace certain cells, like those in our blood and gut, we cannot naturally regrow most other ...

Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...